Sign up for free shipping on all website orders, no minimum required, and get exclusive coupons!
Users can now ask questions to the AI chatbot by clicking the chatbot icon in the bottom-right corner of the website.
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 25316-40-9 | Product Number: D4193
Doxorubicin Hydrochloride
×
![]()
×
Purity: >95.0%(HPLC)
Synonyms:
- Hydroxydaunorubicin Hydrochloride
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
Shipping Information
|
|---|---|---|---|---|---|---|
| 25MG |
$56.00
|
7 | 15 | ≥100 |
|
|
| 100MG |
$140.00
|
35 | 14 | ≥100 |
|
* Items in stock locally typically ship the same day of ordering. Items from Japan stock are able to ship from a US warehouse within 2 weeks after ordering. For additional estimated shipment times, please refer to the Shipping Simulation tool. Note: Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | D4193 |
Purity / Analysis Method 
|
>95.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__7H__2__9NO__1__1·HCl = 579.98 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Light Sensitive,Heat Sensitive |
| Packaging and Container
|
100MG-Glass Bottle with Plastic Insert (View image), 25MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 25316-40-9 |
| Related CAS RN
|
23214-92-8 |
| Reaxys Registry Number | 4229251 |
| PubChem Substance ID | 253660149 |
| Merck Index (14) | 3439 |
| MDL Number | MFCD00077757 |
Specifications
| Appearance | Light yellow to Brown powder to crystal |
| Purity(HPLC) | min. 95.0 area% |
| Specific rotation | +240 to +270 deg(C=0.1,MeOH) |
Properties (reference)
| Specific Rotation | 248° (C=0.1,MeOH) |
| Maximum Absorption Wavelength | 497 nm (H__2O) |
| Solubility in water | Soluble |
| Solubility (soluble in) | Tetrahydrofuran, Methanol |
| Solubility (insoluble in) | Ether, Chloroform, Benzene, Acetone |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. H361 : Suspected of damaging fertility or the unborn child. H373 : May cause damage to organs through prolonged or repeated exposure. H351 : Suspected of causing cancer. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | QI9295900 |
Transport Information:
| HS Number | 2932.99.7000 |
Application
Mitochondria research
Reference
- Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells
Application
Adeno-associated virus vector transduction enhancer
Doxorubicin increases transduction by adeno-associated virus (AAV) vectors.1-3)
References
- 1) Doxorubicin augments rAAV-2 transduction in rat neuronal cells
- 2) Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway
- 3) Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia
Application
Reagent for nephritis (glomerulonephritis) model
References
- Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events
- T. Bertani, A. Poggi, R. Pozzoni, F. Delaini, G. Sacchi, Y. Thoua, G. Mecca, G. Remuzzi, M. B. Donati, Lab. Invest. 1982, 46, 16.
- Adriamycin-induced chronic proteinuria: a structural and functional study
- M. P. O'Donnell, L. Michels, B. Kasiske, L. Raij, W. F. Keane, J. Lab. Clin. Med. 1985 106, 62.
- Effect of dietary protein restriction on renal purines and purine-metabolizing enzymes in adriamycin nephrosis in rats: a mechanism for protection against acute proteinuria involving xanthine oxidase inhibition
- G. M. Ghiggeri, F. Ginevri, G. Cercignani, R. Oleggini, A. Garberi, G. Candiano, P. Altieri, R. Gusmano, Clin. Sci. (Lond). 1990, 79, 647.
- Effect of enalapril on adriamycin-induced nephrosis
- Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats
- Protective effects of sinomenine against doxorubicin-induced nephrosis in rats
Application
Reagent for cardiomyopathy model
References
- Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity
- S. H. Rosenoff, H. M. Olson, D. M. Young, F. Bostick, R. C. Young, J. Natl. Cancer Inst. 1975, 55, 191.
- Experimental animal models of adriamycin cardiotoxicity
- J. H. Doroshow, G. Y. Locker, C. E. Myers, Cancer Treat. Rep. 1979, 63, 855.
- Adriamycin-induced cardiomyopathy. A rat model
- A. Czarnecki, A. Hinek, D. Sołtysiak-Pawluczuk, Pol. J. Pharmacol. Pharm. 1986, 38, 171.
- Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium
- Serial assessment of myocardial properties using cyclic variation of integrated backscatter in an adriamycin-induced cardiomyopathy rat model
- Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I
- Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure
- Doxorubicin dose for congestive heart failure modeling and the use of general ultrasound equipment for evaluation in rats Longitudinal in vivo study.
Application
Reagent for nausea or vomiting model
Reference
- The antiemetic effect of a novel tropisetron patch in anticancer agents-induced kaolin pica model using rats
Application
Reviews on an Anti-tumor Anthracycline Antibiotic, Doxorubicin
Doxorubicin is a widely used anti-tumor anthracycline antibiotic which exhibits good activity against a wide range of tumors. Doxorubicin interacts with DNA by intercalation and inhibition of DNA replication.
References
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin
- Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
- The Power and Potential of Doxorubicin-DNA Adducts
- Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.